Broglio – Consulting: BMS Eric S. Daar – Advisory Committees or Review Panels: Gilead; Consulting: Bristol Myers Squibb, Merck, ViiV, Janssen; Grant/Research

Support: Abbott, Merck, Gilead, ViiV, Pfizer, Bristol Myers Squibb Yong Yuan – Employment: Bristol Myers Squibb Company Anupama Kalsekar- Employment: Bristol Myers Squibb Melanie Quintana – Consulting: BMS Trong Le – Employment: Bristol-Myers Squibb Scott M. Berry-Consulting: BMS The following people have nothing to disclose: Michelle Detry, Brad Spellberg, MAPK inhibitor Roger J. Lewis More than four million people in the US are chronically infected with the hepatitis C virus (HCV), and an estimated 50–75% are unaware of their positive status. Currently, HCV is managed primarily by liver specialists. Few primary care providers (PCPs) have the knowledge and skills to provide HCV care and treatment. As a result of expanded HCV screening recommendations, new testing technologies and more effective treatments, more people infected with HCV will become aware of their status and seek treatment, creating additional demands on an already strained specialty network. In addition, as less complex treatments FK228 molecular weight with more manageable side effects and shorter durations become available, management of HCV infection will move from being a disease managed by specialists to

a disease managed by PCPs. Since 2010, the New York State Department of Health has funded 13 primary care settings to integrate HCV care and treatment. During their first year of providing services, 1,119 patients received HCV care services, of whom 815 (73%) were eligible for treatment. Of those eligible for and offered treatment, 254 (23%) initiated treatment, and 102 (9%) completed treatment. Among those who completed treatment, 37 (33%) achieved a sustained virological response. The overall purpose was to evaluate PCP performance on key

indicators designed to measure the quality of HCV care and treatment. Methods Thirteen HCV Care and Treatment Programs conducted chart reviews on a sample of clients to measure six performance indicators (PI) within four broad categories: HCV treatment, hepatitis vaccination, alcohol counseling and mental health assessment. Data were collected on a spreadsheet and submitted for analysis. Data from the programs were then compared to Elongation factor 2 kinase national data. Results During the review period, 1,119 clients were enrolled in the programs. From these patients, 607 (54%) records were reviewed for PI. 1 00 % had genotype testing prior to treatment; 1 00% had RNA testing prior to treatment; 89 % and 86% received HAV and HBV vaccine, respectively; 89% received alcohol counseling and 83% had mental health assessment prior to treatment initiation. When compared to national data, these programs performed better for each indicator. Conclusions As the demand for HCV care and treatment increases, expanding the capacity to treat HCV beyond liver specialists is critical.